MidFirst Bank’s Filana Therapeutics FLNA Stock Holding History

MidFirst Bank’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19K	Hold	1,000	–	–	﹤0.01%	772
2026 Q1	$1.69K	Hold	1,000	–	–	﹤0.01%	702
2025 Q4	$1.98K	Buy	+1,000	New	+$3.2K	﹤0.01%	681

Other funds holding FLNA

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

MidFirst Bank's FLNA Position: Q2 2026 in Review

MidFirst Bank held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 1,000 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #772.

MidFirst Bank first reported a position in FLNA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.98K in Q4 2025. 62 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

MidFirst Bank held 1,000 shares of Filana Therapeutics worth $1.19K as of Q2 2026.
MidFirst Bank left its Filana Therapeutics share count unchanged in Q2 2026.
Filana Therapeutics made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #772 holding.
MidFirst Bank first reported a position in Filana Therapeutics in Q4 2025 and has held it in 3 quarters since.
MidFirst Bank's Filana Therapeutics position peaked at $1.98K in Q4 2025.
62 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.